Phase II Study of KRP-209- A Double-Blind, Placebo-Controlled Clinical Trial to Evaluate Efficacy and Safety of KRP-209 in Patients with Subjective Tinnitus
Phase of Trial: Phase II
Latest Information Update: 07 Nov 2017
At a glance
- Drugs Neramexane (Primary)
- Indications Tinnitus
- Focus Therapeutic Use
- Sponsors Kyorin Pharmaceutical
- 06 Nov 2017 Status changed from active, no longer recruiting to completed.
- 02 Nov 2016 Status changed from recruiting to active, no longer recruiting.
- 09 Jun 2016 New trial record